Personal Genome Diagnostics Inc. (PGDx), a provider of advanced cancer genome testing products and services, today announced that co-founders Luis Diaz, MD, and Victor Velculescu, MD, PhD, have won the EY Entrepreneur Of The Year® 2016 Award in the Maryland region.
Alexandria Real Estate Equities, the owner and developer of the Alexandria Center for Life Science on the East Side of Manhattan, has just launched an incubator space for biotech start-ups.
The new life science laboratory and office platform, which will be called Alexandria Launchlabs, promises 15,000 s/f of space that provides “the necessary resources and collaborative environment to start transforming novel ideas into innovative, early-stage companies that develop products to improve human health.”
Join us for a thrilling evening of start-up pitches from multiple sectors in healthcare including: Services, Health IT, Biotechnology, Medical Devices and Diagnostics. Applications are still being accepted, so if you not afraid of getting nipped by one of our judges, send your information to jhausfeld@sopenet.org.
POSITION TITLE: Chief Executive Officer
REPORTING TO: Board of Directors
THE COMPANY: TEDCO (Maryland Technology Development Corporation)
“The economic contribution to the Maryland economy of TEDCO’s five core research, technology transfer, and commercialization programs totaled almost $1 billion in 2015, generating a total of 4,358 jobs” – Battelle Technology Partnership Practice, Report on Economic Impacts of TEDCO
TEDCO was created by the Maryland State Legislature in 1998 to facilitate the transfer and commercialization of technology from Maryland’s research universities and federal labs into the marketplace and to assist in the creation and growth of technology-based businesses in all regions of the State. TEDCO is an independent organization that strives to be Maryland’s lead source for entrepreneurial business assistance and seed funding for the development of start-up companies in Maryland’s innovation economy. In Maryland and beyond, TEDCO is a resource of mentoring, funding and networking for entrepreneurs and start-ups that need guidance as they bring innovative concepts to market. TEDCO is more than an early stage funding resource. It is the hub of Maryland’s entrepreneurial network where start-ups find mentors, organizational assistance, facilities for daily operations, and a roadmap for success.
Global epidemics are outrunning globally accessible containment and cures. There are now more ways to spread diseases worldwide than safe, effective ways to counter them. Biomedical stakeholders are engaged in finding solutions. Now rumored recommendations pending at a UN High Level Panel may make matters worse. Appointed by outgoing Secretary General Ban Ki-Moon, the Panel is said to be preparing to release its examination of world “Access to Medicines”. Amazingly it is rumored to be encouraging international flouting of U.S. Bayh-Dole-based patent protection and producer pricing prerogatives. This inevitably will undermine our nation’s life science innovation ecosystem, effectively destroying world hopes for effective response to evolving epidemics.
The approval of Professor Patrick O’Shea’s selection by UCC’s governing body is the first external appointment to the role in 50 years.
Most of his academic career has been at University of Maryland and elsewhere in the US, but he stays in touch with the Irish higher education system. The UCC physics graduate is a director of the Wild Geese Network of Irish Scientists, and he hosted University College Dublin president Andrew Deeks earlier this year.
We were pleased to see the interest in our recent blog on the unique number of investigators applying for and receiving NIH research project grants (RPGs). Some of you (through the blog page or through other media) have asked about whether we have similar data for our Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) program. We have generated analogous figures for SBIR and STTR grants, and today’s post shares this investigation of the question, “How many unique researchers are seeking SBIR/STTR funding?”
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the QIAsure Methylation Test, a novel CE-marked molecular diagnostic test for use in differentiating patients’ risk of developing cervical cancer.
Funding and Research Opportunities
The following funding opportunity announcements from the NHLBI or other components of the National Institutes of Health, might be of interest:
Notices:
Program Announcements:
The venture fund working to make sweetgreen and CustomInk into household names has raised more than half a billion dollars to double down on its strategy.
